Why Is Respiratory Disease-Focused Savara Stock Trading Higher On Wednesday?
Why Is Respiratory Disease-Focused Savara Stock Trading Higher On Wednesday?
The latest trial study from Savara Inc (NASDAQ:SVRA) met its primary endpoint.
萨瓦拉公司（纳斯达克股票代码：SVRA）的最新试验研究达到了其主要终点。
The company released results from Phase 3 IMPALA-2 trial of molgramostim 300 mcg administered once daily by inhalation with a matching placebo for autoimmune pulmonary alveolar proteinosis (aPAP).
该公司公布了molgramostim 300 mcg的3期IMPALA-2 试验结果，该试验每天吸入一次，与自身免疫性肺泡蛋白沉着症（apAP）的配套安慰剂一起给药。
Matt Pauls, CEO Savara, praised the results.
萨瓦拉首席执行官马特·保尔斯对业绩表示赞赏。
PAP is a rare lung disease caused by a buildup of proteins, fats, and other substances in the lungs' air sacs (alveoli).
PAP 是一种罕见的肺部疾病，由肺气囊（肺泡）中蛋白质、脂肪和其他物质积聚引起。
Molgramostim is an inhaled form of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF).
Molgramostim 是一种吸入的重组人粒细胞巨噬细胞集落刺激因子 (GM-CSF)。
The treatment difference between molgramostim and placebo for mean change from baseline to Week 24 in hemoglobin-adjusted percent predicted Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO) achieved statistical significance, with a change of 6%.
molgramostim和安慰剂在血红蛋白调整后的预测肺部一氧化碳弥漫容量（DLCO）百分比的平均变化方面，molgramostim和安慰剂之间的治疗差异具有统计学意义，变化为6％。
The DLCO test measures how much carbon monoxide passes from your lungs to the blood.
DLCO 测试测量有多少一氧化碳从您的肺部流入血液。
This statistically significant treatment difference was sustained at Week 48, a secondary endpoint, with a change of 6.90%, demonstrating the durability of the effect.
这种具有统计学意义的治疗差异在第48周（次要终点）得以维持，变化为6.90％，这表明了效果的持久性。
The treatment difference between molgramostim and placebo for mean change from baseline to Week 24 in St. George's Respiratory Questionnaire Total Score (SGRQ) achieved statistical significance.
molgramostim和安慰剂在从基线到第24周的平均变化方面的治疗差异 圣乔治呼吸问卷 总分（SGRQ）具有统计学意义。
SGRQ is a standardized self-completed questionnaire measuring impaired health and perceived well-being ('quality of life') in airway disease. A negative change from baseline corresponds to improvement.
SGRQ 是一份自填的标准化问卷，旨在衡量气道疾病中健康受损和感知的幸福感（“生活质量”）。与基线相比的负变化对应于改善。
The SGRQ total score at 24 weeks was -6.59 and -4.87 at 48 weeks.
24周的SGRQ总分为-6.59，48周时为-4.87。
Two additional secondary endpoints reached nominal significance: SGRQ Activity Score at Week 24 and exercise capacity using a treadmill test at Week 48.
另外两个次要终点达到了名义意义：第24周的SGRQ活动分数和第48周使用跑步机测试的运动能力。
SGRQ Activity assesses the patient's ability to carry out daily physical activity.
SGRQ 活动评估患者进行日常体育锻炼的能力。
SGRQ Activity Score at 24 weeks was -7.81 and -5.99 at 48 weeks.
24 周的 SGRQ 活动分数为 -7.81，48 周时为 -5.99。
Molgramostim was well tolerated. The frequency of adverse events was generally similar between treatment groups.
Molgramostim 的耐受性良好。治疗组之间不良事件的发生频率普遍相似。
Two patients (2.5%) discontinued molgramostim treatment due to adverse events, both of which were considered unrelated to the trial drug.
两名患者（2.5%）因不良事件停止了molgramostim治疗，两者均被认为与试验药物无关。
Price Action: SVRA shares are up 30% at $4.94 during the premarket session at last check Wednesday.
价格走势：在周三的最后一次盘前交易中，SVRA股价上涨了30％，至4.94美元。
Now Read: Sanofi Looks To Sell $20B Icy Hot Division: Likely Bidders Include Advent, PAI Partners, Blackstone, CVC
立即阅读：赛诺菲计划出售200亿美元的Icy Hot Division：可能的竞标者包括Advent、PAI Partners、Blackstone、CVC